capricor therapeutics

News

Capricor, FDA and cell therapy

Capricor shares sink as US FDA declines to approve cell therapy

The U.S. Food and Drug Administration has declined to approve Capricor Therapeutics' cell therapy for a heart condition, the company said on Friday, sending its shares tumbling 30% in early trading. In its "complete response letter,

BioSpace · 1d

Capricor Plunges on FDA Rejection of DMD Cell Therapy

Fierce Biotech · 1d

FDA rejects Capricor’s DMD cell therapy, asks for more data

Capricor: Maintaining Hold Rating In Light Of Deramiocel Complete Response Letter

Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial ...

Morningstar2d

Capricor Therapeutics Provides Regulatory Update on ... - Morningstar

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

STAT1d

Pharmalittle: We’re reading about a FDA offer on drug reviews, a Moderna Covid approval, and more

FDA head Marty Makary said the agency may fast-track drugs from companies that “equalize” the cost of medicines between the U ...

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Frequency Electronics reported earnings of 34 cents per share for the fourth quarter, up from 28 cents per share in the ...

Seeking Alpha1d

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for ...

Capricor Therapeutics is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases.

Stocktwits on MSN5d

Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results